Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalledTzield pushed back after adverse event…
